Jessie Kittle1, Renato D Lopes2, Mingyan Huang2, Marsha L Marquess2, Matthew D Wilson2, John Ascher3, Alok Krishen4, Vic Hasselblad2, Brad J Kolls2, Matthew T Roe2, Darren K McGuire5, Stuart D Russell6, Kenneth W Mahaffey1. 1. Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 3. GlaxoSmithKline, Research Triangle Park, North Carolina. 4. PAREXEL International on behalf of GlaxoSmithKline, Durham, North Carolina. 5. Department of Internal Medicine-Cardiology, University of Texas Southwestern Medical Center, Dallas. 6. Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland.
Abstract
BACKGROUND: In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation. HYPOTHESIS: Retrospective adjudication of clinical trial data will not increase the identification of adverse events. METHODS: We performed a comprehensive retrospective analysis of adverse events in 19 previously completed controlled US clinical trials of bupropion marketed for the treatment of smoking cessation, yielding 9479 subjects (5290 bupropion, 2927 placebo, 1018 active control [ACT], and 244 treated concurrently withbupropion and ACT). All adverse events were sent to the Duke Clinical Research Institute for adjudication by Clinical Events Classification (CEC) physician reviewers. The primary endpoint was a composite of major adverse CV events: CV death, nonfatal myocardial infarction (MI), and nonfatal stroke. RESULTS: Overall, 416 nonfatal CV events in 366 subjects, and 22 deaths, were identified and processed for adjudication. Of these, 7 nonfatal MIs (4 bupropion, 3 placebo, 0 ACT), 5 nonfatal strokes (1 bupropion, 3 placebo, 1 ACT), and 9 CV deaths (4 bupropion, 4 placebo, 1 ACT) were confirmed by the CEC Committee. The primary endpoint occurred in 3/4297 (0.07%) subjects in the bupropion group and in 4/2927 (0.14%) subjects in the placebo group (log-rank P value: 0.613). CONCLUSIONS:CV events in bupropion clinical trials for smoking cessation were uncommon, with no observed increase among subjects assigned to bupropion vs placebo. However, this effort was limited by a paucity of quality data.
RCT Entities:
BACKGROUND: In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation. HYPOTHESIS: Retrospective adjudication of clinical trial data will not increase the identification of adverse events. METHODS: We performed a comprehensive retrospective analysis of adverse events in 19 previously completed controlled US clinical trials of bupropion marketed for the treatment of smoking cessation, yielding 9479 subjects (5290 bupropion, 2927 placebo, 1018 active control [ACT], and 244 treated concurrently with bupropion and ACT). All adverse events were sent to the Duke Clinical Research Institute for adjudication by Clinical Events Classification (CEC) physician reviewers. The primary endpoint was a composite of major adverse CV events: CV death, nonfatal myocardial infarction (MI), and nonfatal stroke. RESULTS: Overall, 416 nonfatal CV events in 366 subjects, and 22 deaths, were identified and processed for adjudication. Of these, 7 nonfatal MIs (4 bupropion, 3 placebo, 0 ACT), 5 nonfatal strokes (1 bupropion, 3 placebo, 1 ACT), and 9 CV deaths (4 bupropion, 4 placebo, 1 ACT) were confirmed by the CEC Committee. The primary endpoint occurred in 3/4297 (0.07%) subjects in the bupropion group and in 4/2927 (0.14%) subjects in the placebo group (log-rank P value: 0.613). CONCLUSIONS: CV events in bupropion clinical trials for smoking cessation were uncommon, with no observed increase among subjects assigned to bupropion vs placebo. However, this effort was limited by a paucity of quality data.
Authors: Koon K Teo; Stephanie Ounpuu; Steven Hawken; M R Pandey; Vicent Valentin; David Hunt; Rafael Diaz; Wafa Rashed; Rosario Freeman; Lixin Jiang; Xiaofei Zhang; Salim Yusuf Journal: Lancet Date: 2006-08-19 Impact factor: 79.321
Authors: Prabhat Jha; Chinthanie Ramasundarahettige; Victoria Landsman; Brian Rostron; Michael Thun; Robert N Anderson; Tim McAfee; Richard Peto Journal: N Engl J Med Date: 2013-01-24 Impact factor: 91.245
Authors: Kenneth W Mahaffey; Gail Hafley; Sheila Dickerson; Shana Burns; Sandra Tourt-Uhlig; Jennifer White; L Kristin Newby; Michel Komajda; John McMurray; Robert Bigelow; Philip D Home; Renato D Lopes Journal: Am Heart J Date: 2013-06-05 Impact factor: 4.749
Authors: Renato D Lopes; Sheila Dickerson; Gail Hafley; Shana Burns; Sandra Tourt-Uhlig; Jennifer White; L Kristin Newby; Michel Komajda; John McMurray; Robert Bigelow; Philip D Home; Kenneth W Mahaffey Journal: Am Heart J Date: 2013-06-22 Impact factor: 4.749
Authors: Mark J Eisenberg; Sonia M Grandi; André Gervais; Jennifer O'Loughlin; Gilles Paradis; Stéphane Rinfret; Nizal Sarrafzadegan; Sat Sharma; Claude Lauzon; Rakesh Yadav; Louise Pilote Journal: J Am Coll Cardiol Date: 2013-02-05 Impact factor: 24.094
Authors: Sarah Dahlberg; Ellen T Chang; Sheila R Weiss; Pamela Dopart; Errol Gould; Mary E Ritchey Journal: Diabetes Metab Syndr Obes Date: 2022-09-29 Impact factor: 3.249